Charles River Laboratories International (NYSE:CRL) Price Target Cut to $239.00

Charles River Laboratories International (NYSE:CRL) had its price objective decreased by stock analysts at Robert W. Baird from $271.00 to $239.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s target price points to a potential upside of 13.33% from the stock’s current price.

CRL has been the subject of a number of other reports. Barclays assumed coverage on shares of Charles River Laboratories International in a report on Friday, June 28th. They issued an “equal weight” rating and a $230.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Charles River Laboratories International in a research report on Thursday, June 6th. They issued a “buy” rating and a $290.00 price target on the stock. Mizuho began coverage on Charles River Laboratories International in a report on Friday, June 7th. They issued a “neutral” rating and a $235.00 price target on the stock. TD Cowen reduced their price objective on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research note on Monday, May 13th. Finally, Argus reaffirmed a “hold” rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $252.29.

Charles River Laboratories International Stock Up 4.0 %

CRL stock opened at $210.88 on Wednesday. The firm’s 50-day moving average is $214.81 and its two-hundred day moving average is $230.87. The company has a market capitalization of $10.86 billion, a price-to-earnings ratio of 24.81, a price-to-earnings-growth ratio of 1.92 and a beta of 1.38. Charles River Laboratories International has a 52 week low of $161.65 and a 52 week high of $275.00. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.05 by $0.22. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. On average, analysts forecast that Charles River Laboratories International will post 11 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $226.97, for a total value of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares in the company, valued at approximately $5,282,953.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $101,319,000. Point72 Asset Management L.P. grew its position in Charles River Laboratories International by 499.1% in the fourth quarter. Point72 Asset Management L.P. now owns 368,984 shares of the medical research company’s stock worth $87,228,000 after acquiring an additional 307,398 shares in the last quarter. Meritage Group LP increased its stake in shares of Charles River Laboratories International by 30.8% during the 4th quarter. Meritage Group LP now owns 1,155,376 shares of the medical research company’s stock worth $273,131,000 after purchasing an additional 271,743 shares during the last quarter. Epoch Investment Partners Inc. raised its holdings in shares of Charles River Laboratories International by 2,733.4% during the 1st quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock valued at $67,060,000 after purchasing an additional 238,766 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of Charles River Laboratories International by 5,003.9% in the 4th quarter. KBC Group NV now owns 215,639 shares of the medical research company’s stock valued at $50,977,000 after purchasing an additional 211,414 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).